- Home
- EBS vs REPL Comparison
EBS vs REPL Comparison
Compare EBS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EBS | REPL |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.3M | 781.3M |
| IPO Year | 2006 | 2018 |
Fundamental Metrics
Financial Performance| Metric | EBS | REPL |
|---|---|---|
| Price | $12.05 | $7.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $15.00 | $12.00 |
| AVG Volume (30 Days) | 968.8K | ★ 1.5M |
| Earning Date | 03-02-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | ★ $788,900,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.21 | N/A |
| P/E Ratio | $8.85 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.02 | $2.68 |
| 52 Week High | $14.06 | $14.80 |
Technical Indicators
Market Signals| Indicator | EBS | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 40.02 |
| Support Level | $10.60 | $6.77 |
| Resistance Level | $12.58 | $7.91 |
| Average True Range (ATR) | 0.79 | 0.54 |
| MACD | -0.15 | -0.06 |
| Stochastic Oscillator | 39.60 | 35.48 |
Price Performance
Historical ComparisonAbout EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.